Loading
Pioneer of CRISPR-Cas9 genome editing in human cells, the tool behind cancer dependency screens and edited cell therapies.
Feng Zhang is a Core Institute Member of the Broad Institute of MIT and Harvard and the James and Patricia Poitras Professor of Neuroscience at MIT. He is a pioneer of CRISPR-Cas9 genome editing in human cells, having adapted the system for mammalian genome editing in 2013 and later discovered the Cas12 and Cas13 systems. His selected paper reports multiplex genome engineering using CRISPR/Cas systems. His tools underpin genome-wide cancer dependency screens and next-generation engineered and off-the-shelf cell therapies, and his laboratory continues to work on molecular tools and delivery.
| Title | Journal | Year |
|---|---|---|
| Multiplex genome engineering using CRISPR/Cas systems | Science | 2013 |
Shares Broad Institute of MIT and Harvard, CRISPR functional genomics.
Shares Broad Institute of MIT and Harvard, CRISPR functional genomics.
Shares Broad Institute of MIT and Harvard, CRISPR functional genomics.
Shares CRISPR functional genomics, Allogeneic (off-the-shelf) cell therapy.
Shares CRISPR functional genomics, Allogeneic (off-the-shelf) cell therapy.
Shares Broad Institute of MIT and Harvard, CRISPR functional genomics.
Shares Broad Institute of MIT and Harvard, CRISPR functional genomics.
Shares CRISPR functional genomics, Allogeneic (off-the-shelf) cell therapy.